Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.

Ketas TJ, Frank I, Klasse PJ, Sullivan BM, Gardner JP, Spenlehauer C, Nesin M, Olson WC, Moore JP, Pope M.

J Virol. 2003 Feb;77(4):2762-7.

PMID:
12552019
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types.

Ketas TJ, Klasse PJ, Spenlehauer C, Nesin M, Frank I, Pope M, Strizki JM, Reyes GR, Baroudy BM, Moore JP.

AIDS Res Hum Retroviruses. 2003 Mar;19(3):177-86.

PMID:
12689409
[PubMed - indexed for MEDLINE]
3.

Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion.

Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T, Olson WC.

J Infect Dis. 2001 Apr 1;183(7):1121-5. Epub 2001 Mar 8.

PMID:
11237840
[PubMed - indexed for MEDLINE]
Free Article
4.

Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.

Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E.

J Virol. 2000 Sep;74(18):8358-67.

PMID:
10954535
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

HIV fusion and its inhibition.

LaBranche CC, Galasso G, Moore JP, Bolognesi DP, Hirsch MS, Hammer SM.

Antiviral Res. 2001 May;50(2):95-115. Review. No abstract available.

PMID:
11369431
[PubMed - indexed for MEDLINE]
6.

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.

Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ, Olson WC.

J Virol. 2001 Jan;75(2):579-88.

PMID:
11134270
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells.

Zhang Y, Lou B, Lal RB, Gettie A, Marx PA, Moore JP.

J Virol. 2000 Aug;74(15):6893-910.

PMID:
10888629
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.

Reeves JD, Miamidian JL, Biscone MJ, Lee FH, Ahmad N, Pierson TC, Doms RW.

J Virol. 2004 May;78(10):5476-85.

PMID:
15113926
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor on untransformed human brain and lymphoid cells.

Willey SJ, Reeves JD, Hudson R, Miyake K, Dejucq N, Schols D, De Clercq E, Bell J, McKnight A, Clapham PR.

J Virol. 2003 Jun;77(11):6138-52.

PMID:
12743271
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, Pohlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E, Doms RW.

Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54. Epub 2002 Nov 20.

PMID:
12444251
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Resistance to HIV-1 entry inhibitors.

Olson WC, Maddon PJ.

Curr Drug Targets Infect Disord. 2003 Dec;3(4):283-94. Review.

PMID:
14754430
[PubMed - indexed for MEDLINE]
13.

Coreceptor competition for association with CD4 may change the susceptibility of human cells to infection with T-tropic and macrophagetropic isolates of human immunodeficiency virus type 1.

Lee S, Lapham CK, Chen H, King L, Manischewitz J, Romantseva T, Mostowski H, Stantchev TS, Broder CC, Golding H.

J Virol. 2000 Jun;74(11):5016-23.

PMID:
10799575
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death.

Barretina J, Blanco J, Armand-Ugón M, Gutiérrez A, Clotet B, Esté JA.

Antivir Ther. 2003 Apr;8(2):155-61.

PMID:
12741628
[PubMed - indexed for MEDLINE]
15.

Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors.

Labrosse B, Labernardière JL, Dam E, Trouplin V, Skrabal K, Clavel F, Mammano F.

J Virol. 2003 Jan;77(2):1610-3.

PMID:
12502877
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Susceptibility of HIV type 1 to the fusion inhibitor T-20 is reduced on insertion of host intercellular adhesion molecule 1 in the virus membrane.

Beauséjour Y, Tremblay MJ.

J Infect Dis. 2004 Sep 1;190(5):894-902. Epub 2004 Jul 23.

PMID:
15295693
[PubMed - indexed for MEDLINE]
Free Article
17.
18.
19.

Capture of an early fusion-active conformation of HIV-1 gp41.

Furuta RA, Wild CT, Weng Y, Weiss CD.

Nat Struct Biol. 1998 Apr;5(4):276-9. Erratum in: Nat Struct Biol 1998 Jul;5(7):612.

PMID:
9546217
[PubMed - indexed for MEDLINE]
20.

The temperature arrested intermediate of virus-cell fusion is a functional step in HIV infection.

Henderson HI, Hope TJ.

Virol J. 2006 May 25;3:36.

PMID:
16725045
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk